EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers

Valentin Skryabin, Anton Masyakin, Sergei Pozdniakov, Igor Shatokhin, Svetlana Sokolova, Valentina Ivanchenko, Polina Makartseva

Psychopharmacology Bulletin · 2026

DOI: 10.64719/pb.15425 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Valentin Skryabin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Ru…. Hauptthemen laut MEDLINE: MicroRNAs, Precision Medicine, Pharmacogenomic Testing, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute alcoholic hallucinosis (ICD-10 F10.52) necessitates urgent antipsychotic treatment but carries high risks of adverse drug reactions (ADRs). While pharmacogenetic clinical decision support systems (CDSS) show promise, their utility is limited by static genotyping and incomplete biomarker integration.

Purpose

This study aimed to develop and validate a multi-omics framework integrating pharmacogenetic testing, CYP phenotyping, and microRNA biomarkers to personalize antipsychotic therapy and improve outcomes in acute alcoholic hallucinosis. Material and methods: In this three-arm study, 300 Russian inpatients with acute alcoholic hallucinosis underwent: 1) Randomized pharmacogenetic-guided vs. standard therapy (n = 100); 2) CYP2D6/CYP3A4 phenotyping via urinary pinoline/cortisol ratios (n = 100); and 3) microRNA quantification (miR-27b, miR-370-3p; n = 100). Efficacy (PANSS) and safety (UKU) were assessed over 6 days.

Results

Pharmacogenetic guidance significantly reduced ADRs (UKU day 6: 5.0 [3.0 − 8.0] vs. 12.0 [10.0 − 16.0], p < 0.01) with comparable efficacy (PANSS≈1.0). Phenotyping identified 28% CYP2D6 poor metabolizers (vs. 15% by genotyping), exhibiting 40% higher haloperidol levels (r = 0.72, p < 0.001). Baseline miR-27b inversely correlated with day-3 PANSS (r = − 0.54, p < 0.001), while miR-370-3p predicted poorer day-6 response (ΔPANSS r = 0.48, p < 0.001) and higher UKU scores (r = 0.52, p < 0.001). Integrating microRNAs with phenotyping improved ADR prediction accuracy by 22% versus single modalities.

Conclusion

A multi-omics approach synergistically optimizes antipsychotic therapy by addressing genotyping limitations through dynamic phenotyping and microRNA-based prognostication, significantly enhancing safety in this high-risk population. Psychopharmacology Bulletin. 2026;56(1):82–91.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsPrecision MedicinePharmacogenomic TestingAntipsychotic AgentsPsychoses, AlcoholicHumansMaleFemaleAdultMiddle AgedCytochrome P-450 CYP3APhenotypeBiomarkersCytochrome P-450 CYP2D6

Stichwörter der Autor:innen

acute alcoholic hallucinosisantipsychotic therapymetabolic phenotypingmicroRNA biomarkerspersonalized medicinepharmacogenetics

Substanzen

MicroRNAsAntipsychotic AgentsCytochrome P-450 CYP3ABiomarkersCytochrome P-450 CYP2D6CYP3A4 protein, human

Autor:innen und Institutionen

  • Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Masyakin, PhD, MD, director, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Pozdniakov, researcher, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Shatokhin, researcher, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Sokolova, researcher, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Ivanchenko, laboratory research assistant, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.

Zitieren

APA

Skryabin, V., Masyakin, A., Pozdniakov, S., Shatokhin, I., Sokolova, S., Ivanchenko, V., & Makartseva, P. (2026). Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.15425

Vancouver

Skryabin V, Masyakin A, Pozdniakov S, Shatokhin I, Sokolova S, Ivanchenko V, et al. Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.15425

BibTeX
@article{Skryabin2026,
  author = {Skryabin, Valentin and Masyakin, Anton and Pozdniakov, Sergei and Shatokhin, Igor and Sokolova, Svetlana and Ivanchenko, Valentina and Makartseva, Polina},
  title = {Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  doi = {10.64719/pb.15425}
}
Kostenlos starten →